Trial Profile
A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs SER 109 (Primary)
- Indications Clostridium difficile infections
- Focus Registrational; Therapeutic Use
- Acronyms ECOSPOR III
- Sponsors Seres Therapeutics
- 12 Oct 2023 Results of post hoc analysis assessing from ECOSPOR III trial assessing impact of a microbiota-based oral therapeutic (fecal microbiota spores, live [VOWSTTM Oral Spores; VOS, formerly SER-109]) compared with placebo, on AR gene (ARG) abundance in patients with recurrent Clostridioides difficile infection published in the Clinical Infectious Diseases
- 12 Oct 2023 According to a Seres Therapeutics media release, results from post-hoc analysis of the ECOSPOR III and ECOSPOR IV Phase 3 studies will be presented at ID Week 2023
- 04 Aug 2023 Results of post hoc analysis assessing efficacy of VOS compared with placebo in patients with comorbidities and other risk factors for rCDI published in the Clinical Infectious Diseases